



October 26, 2015

## Momenta Pharmaceuticals Announces Publication of Two Glatopa (glatiramer acetate injection) Manuscripts

### Data Support Demonstration of Equivalence Between Glatopa and Daily COPAXONE 20 mg

CAMBRIDGE, Mass., Oct. 26, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the recent publication of two peer-reviewed manuscripts that summarize the structural and biological assays used to evaluate equivalence between Glatopa™ and daily COPAXONE® 20 mg:

- "Demonstration of Equivalence of a Generic Glatiramer Acetate (Glatopa™)," *Journal of the Neurological Sciences*, which can be found at: <http://www.sciencedirect.com/science/article/pii/S0022510X15024740>
- "Equivalent Gene Expression Profiles between Glatopa™ and COPAXONE®" in *PLOS ONE*, which can be found at: <http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0140299>

### About Glatopa™

Once daily Glatopa (glatiramer acetate injection) is the first FDA-approved generic version of daily COPAXONE® 20 mg for patients with relapsing forms of multiple sclerosis. Produced entirely in the United States, once daily Glatopa has been determined by the FDA to be therapeutically equivalent to daily COPAXONE 20 mg, and is an "AP" rated, fully-substitutable product. As a therapeutically equivalent generic product, once daily Glatopa contains the same active ingredients, route of administration, strength, and dosage form, and can be substituted with the full expectation that Glatopa will produce the same clinical effect and safety profile as daily COPAXONE 20 mg. Daily COPAXONE 20 mg is one of the leading products marketed to treat multiple sclerosis, and is frequently prescribed as a first-line therapy in newly diagnosed patients.

### About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural and functional analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

To receive additional information about Momenta, please visit the website at [www.momentapharma.com](http://www.momentapharma.com), which does not form a part of this press release.

The company's logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

### Forward Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to its beliefs and intentions related to our Glatopa product, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "hope," "target," "project," "goals," "potential," "predict," "might," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors referred to in the Company's Annual Report on Form 10-Q for the quarter ended June 30, 2015 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Momenta from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained

herein. Momenta is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

COPAXONE is a registered trademark of Teva Pharmaceuticals. Glatopa is a trademark of Novartis AG.

Investor Relations:

Sarah Carmody

Momenta Pharmaceuticals

1-617-395-5189

[IR@momentapharma.com](mailto:IR@momentapharma.com)

Media Relations:

Karen Sharma

MacDougall Biomedical Communications

1-781-235-3060

[Momenta@macbiocom.com](mailto:Momenta@macbiocom.com)

 Primary Logo

Source: Momenta Pharmaceuticals, Inc.

News Provided by Acquire Media